相似文献
1
Does low-dose ASA help prevent cardiovascular events in women?
Can Fam Physician. 2006 Mar;52(3):319-21.
2
The impact of upper gastrointestinal symptoms on nonadherence to, and discontinuation of, low-dose acetylsalicylic acid in patients with cardiovascular risk.
Am J Cardiovasc Drugs. 2010;10(5):281-8. doi: 10.2165/11584410-000000000-00000.
3
Cardiovascular and upper gastrointestinal bleeding consequences of low-dose acetylsalicylic acid discontinuation.
Thromb Haemost. 2013 Dec;110(6):1298-304. doi: 10.1160/TH13-04-0326. Epub 2013 Sep 5.
4
Chronotherapy with low-dose aspirin for prevention of complications in pregnancy.
Chronobiol Int. 2013 Mar;30(1-2):260-79. doi: 10.3109/07420528.2012.717455. Epub 2012 Sep 24.
5
Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study.
Neurology. 2011 Feb 22;76(8):740-6. doi: 10.1212/WNL.0b013e31820d62b5. Epub 2011 Jan 26.
6
Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation.
Am J Cardiovasc Drugs. 2010;10(2):125-41. doi: 10.2165/11318440-000000000-00000.
7
Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy.
Am Heart J. 2008 Dec;156(6):1080-1088.e1. doi: 10.1016/j.ahj.2008.07.026. Epub 2008 Nov 1.
8
In the dose range of 0.5-2.0 mg/kg, acetylsalicylic acid does not affect prostacyclin production in hypertensive pregnancies.
Acta Obstet Gynecol Scand. 1999 Feb;78(2):82-8.
9
Burden of upper gastrointestinal symptoms in patients receiving low-dose acetylsalicylic acid for cardiovascular risk management: a prospective observational study.
Am J Cardiovasc Drugs. 2013 Feb;13(1):27-35. doi: 10.1007/s40256-012-0001-4.
10
Incidence of aspirin resistance and its relationship with cardiovascular risk factors and graft function in renal transplant recipients.
Transplant Proc. 2008 Dec;40(10):3485-8. doi: 10.1016/j.transproceed.2008.06.108.
本文引用的文献
1
Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology.
Eur Heart J. 2004 Jan;25(2):166-81. doi: 10.1016/j.ehj.2003.10.013.
2
Should patients who have not had a cardiac event take ASA to prevent one?
Can Fam Physician. 2002 Jan;48:55-7.
3
Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force.
Ann Intern Med. 2002 Jan 15;136(2):161-72. doi: 10.7326/0003-4819-136-2-200201150-00016.
4
Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.
Heart. 2001 Mar;85(3):265-71. doi: 10.1136/heart.85.3.265.
5
6
Systemic availability of acetylsalicylic acid in normal men and women and its effect on in vitro platelet aggregability.
Eur J Clin Pharmacol. 1983;24(5):679-82. doi: 10.1007/BF00542222.
7
Comparison of the effect of acetylsalicylic acid on platelet function in male and female patients with ischemic stroke.
Thromb Res. 1987 Aug 1;47(3):295-304. doi: 10.1016/0049-3848(87)90143-5.
Zotero 插件